1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: other
Emmessar Biotech & Nutrition Ltd.

Emmessar Biotech & Nutrition Ltd.

BBSE:EMMESSA
22.32
INR
-1.98
(-8.15%)
0.79EPS
31.29P/E
123.40MMarket Cap
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
2.74
4.38
3.95
5.27
2.51
1.26
6.8
13.99
0.73
2.04
1.11
1.22
0.74
0.67
Basic EPS, GAAP
-0.61
-0.24
-0.93
2.38
1.83
1.07
1.51
2.9
0.95
1.01
1.5
0.63
0.87
0.79
Free Cash Flow per Basic Share
-0.01
-0.02
0.84
-0.11
-0.08
0.78
2.06
0.93
3.93
0.7
1.29
0.45
0.51
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
3.16
2.75
1.82
4.18
5.97
7.02
8.53
11.41
12.35
13.34
14.82
15.43
16.24
- -
Tangible Book Value per Share
3.16
2.75
1.82
4.18
5.97
7.02
8.53
11.41
12.35
13.34
14.82
15.43
16.24
- -
Basic Weighted Avg Shares
5
5
5
5
5
5
5
5
5
5
5
5
5
5
Sales/Revenue/Turnover
14
22
20
26
13
6
34
70
4
10
6
6
4
3
Operating Margin (%)
-17.11
-9.65
3.71
8.71
-37.23
-113.87
-13.65
11.32
-251.9
-74.89
-211.85
-171.55
-391.69
-453
Depreciation Expense
2
1
- -
- -
1
1
1
1
1
1
1
1
1
1
Net Income, GAAP
-3
-1
-5
12
9
5
8
14
5
5
7
3
4
4
Effective Tax Rate (%)
- -
- -
- -
0.35
- -
- -
- -
35.7
48.96
47.9
7.75
67.01
24.79
22.51
Profit Margin (%)
-22.44
-5.38
-23.57
45.14
72.9
84.66
22.19
20.74
130.28
49.43
135.04
51.74
117.5
117.47
Working Capital
1
3
6
9
9
15
22
40
45
55
63
69
74
- -
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
16
14
9
21
30
35
43
57
62
67
74
77
81
- -
Return on Invested Capital (%)
- -
- -
- -
15.13
- -
- -
- -
9.97
-5.68
-6.08
-15.22
-4.35
-13.43
- -
Return on Capital (%)
- -
- -
- -
79.09
- -
- -
- -
29.1
8.01
7.8
10.51
4.16
5.53
- -
Return on Common Equity (%)
-17.39
-7.98
-40.75
79.27
36
16.42
19.4
29.1
8.01
7.85
10.66
4.18
5.51
- -

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
5
5
5
Market Capitalization
147
118
123

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
81
- -
Cash, Cash Equivalents & STI
- -
73
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
1
- -
Total Current Liabilities
- -
6
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
28.22%
7.34%
5.27%
Free Cash Flow
-88.12%
54.57%
14.65%
Net Income, GAAP
-31.89%
-6.49%
37.84%
Sales/Revenue/Turnover
48.62%
1.95%
-39.3%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
1
3
1
1
6
2026
1
1
1
1
4
2027
1
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
0.18
0.56
0.03
-0.16
0.63
2026
0.34
0.23
0.23
0.07
0.87
2027
0.26
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Mathurakavi Srinivas Ayyangar
Full Time Employees
18
Sector
Health technology
Industry
Pharmaceuticals: other
Address
29, Kamer Building Mumbai MA India 400001
IPO Date
Dec 14, 1994
Website
ebnl.org
Similar Companies
Cipla Ltd (NSE:CIPLA)
Aurobindo Pharma Ltd (NSE:AUROPHARMA)
Lupin Limited (NSE:LUPIN)
Granules India Limited (NSE:GRANULES)
Revolution Medicines, Inc. (NASDAQ:RVMD)
Egyptian International Pharmaceutical Industries Co. (EGX:PHAR)
Business
Emmessar Biotech & Nutrition Limited manufactures and markets healthcare, nutritional, and biotechnology products with a focus on nutraceuticals, cosmeceuticals, and fine chemicals; its core offerings include CalmCream and CalmCream RESQ for multifunctional skin repair and burns from sun, radiation, heat, or chemicals, Cute-N-Comely and MagiCream for cosmetic restoration and post-surgical scars, Muscle Flex Gel for muscle pain relief, Supportt Joint and Supportt Bones for joint and bone support, as well as cough syrups, capsules, lotions, bone powders, and VedaCeuticals combining Ayurveda, biotechnology, and nanotechnology; the company also produces super specialty fine chemicals such as vital micro nutrients, Biosulf, Para Quinone Dioxime, and Methyl Sulfonyl Methane for biotech research and pharmaceutical applications. Founded on March 17, 1992, as Emmessar Chemical Industries Limited and renamed Emmessar Biotech & Nutrition Limited in 2000 to reflect its pivot to biotechnology and healthcare, the company maintains DSIR-recognized R&D facilities and operates from its registered office in Taloja, Raigad, Maharashtra, with a corporate office in Mumbai, India; it serves domestic and international markets through healthcare, fine chemicals, and lease segments, targeting consumers with chronic skin, muscle, bone, pain, and general health needs. In recent developments, the company held its 33rd annual general meeting on September 26, 2025, released unaudited financial results showing net profit growth to Rs 0.17 crore for the June 2025 quarter amid revenue fluctuations, announced management changes under Regulation 30 in February 2025, and continues its long-standing 1998 collaboration with California-based Vibrant Life for product innovation while pursuing path-breaking VedaCeuticals advancements as of fiscal year 2025.